Oxford-based biotech Evox therapeutics, a frontrunner in harnessing and engineering the pure supply capabilities of extracellular vesicles (EVs), often known as exosomes, has bought Codiak Biosciences’ engEx-AAV™ expertise platform. The settlement contains all mental property rights, in addition to securing unique entry to sure engineering and manufacturing rights related to it. This expertise allows energetic loading of adeno-associated virus (AAV) into exosomes adopted by their launch when the AAV-loaded exosomes are delivered into recipient cells. This has been demonstrated to be an efficient means to enhance AAV supply, to extend the breadth of expression in pre-clinical fashions and to protect AAVs from neutralising antibodies.

Focused on creating a completely new class of therapeutics for the remedy of extreme uncommon ailments, Evox makes use of its proprietary DeliverEX® expertise to engineer exosomes to facilitate drug supply to organs of curiosity, together with the mind and the central nervous system. This strategy has potential to deal with a number of the limitations of genetic medicines equivalent to gene remedy, gene enhancing and RNA therapeutics by enabling secure non-immunogenic repeated supply to cells and tissues which can be at present out of attain utilizing different drug supply applied sciences. It is backed by main life sciences enterprise capital teams together with Redmile and OrbiMed, and is supported by a complete mental property portfolio.

“We are pleased to now own this technology and look forward to applying it in future exosome AAV programs. This acquisition further adds to our dominant intellectual property portfolio of patents that cover key aspects needed to develop and commercialise exosome therapeutics including their design, composition, and manufacture,” stated Per Lundin, PhD, Chief Business Officer & Co-Founder of Evox Therapeutics. “This is part of our long-term business strategy of leveraging improved exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors.”

More data online